NASDAQ:NBSE NeuBase Therapeutics (NBSE) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free NBSE Stock Alerts $0.43 -0.01 (-2.21%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$0.43▼$0.4350-Day Range$0.48▼$1.0752-Week Range$0.42▼$5.40Volume32,132 shsAverage Volume239,794 shsMarket Capitalization$1.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NeuBase Therapeutics alerts: Email Address NeuBase Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.66% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.35Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.63 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for NeuBase Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.66% of the float of NeuBase Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuBase Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuBase Therapeutics has recently decreased by 59.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuBase Therapeutics does not currently pay a dividend.Dividend GrowthNeuBase Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeuBase Therapeutics has received a 72.00% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for NeuBase Therapeutics is -1.03. Previous Next 1.9 News and Social Media Coverage News SentimentNeuBase Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NeuBase Therapeutics this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuBase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.90% of the stock of NeuBase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.37% of the stock of NeuBase Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuBase Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuBase Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuBase Therapeutics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe AI Defense Stock Set to SoarTo protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>> About NeuBase Therapeutics Stock (NASDAQ:NBSE)NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Read More NBSE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBSE Stock News HeadlinesMarch 27, 2024 | msn.comWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 26, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 26, 2024 | investorplace.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?March 25, 2024 | bizjournals.comNeuBase Therapeutics sets shareholder meeting on dissolution planFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics IncFebruary 20, 2024 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE)January 20, 2024 | ca.finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)March 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.December 22, 2023 | bizjournals.comCMU halts licensing agreement with NeuBase TherapeuticsNovember 27, 2023 | finance.yahoo.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 6, 2023 | morningstar.comNeuBase Therapeutics Inc NBSEOctober 6, 2023 | finance.yahoo.comNeuBase Therapeutics, Inc. (NBSE.MX)September 12, 2023 | benzinga.comMassive Insider Trade At NeuBase TherapeuticsSeptember 12, 2023 | msn.comNeuBase falls after largest shareholder disposes of part stakeSeptember 8, 2023 | finance.yahoo.comNeuBase Therapeutics Issues Statement Regarding Filing By ShareholderSeptember 6, 2023 | markets.businessinsider.comWhy Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?August 16, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)August 6, 2023 | fool.comNeuBase Therapeutics (NASDAQ: NBSE)August 3, 2023 | finance.yahoo.comNeuBase Therapeutics to Explore Strategic AlternativesAugust 1, 2023 | bizjournals.comPittsburgh biotech firm amends stock incentive planJune 30, 2023 | finance.yahoo.comNeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesJune 29, 2023 | finance.yahoo.comNeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to RedosingJune 28, 2023 | finance.yahoo.comNeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesJune 14, 2023 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Announces 1-for-20 Reverse Stock SplitJune 14, 2023 | msn.comNeuBase Therapeutics to undertake 1-for-20 reverse share splitJune 14, 2023 | finance.yahoo.comNeuBase Announces 1-for-20 Reverse Stock SplitSee More Headlines Receive NBSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/23/2021Today3/28/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NBSE CUSIPN/A CIK1173281 Webwww.neubasetherapeutics.com Phone(164) 645-1790FaxN/AEmployees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.74% Return on Assets-60.13% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.04 per share Price / Book0.04Miscellaneous Outstanding Shares3,729,000Free Float3,211,000Market Cap$1.62 million OptionableNot Optionable Beta0.88 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Todd P. Branning (Age 53)Interim CEO, CFO & Secretary Comp: $427.44kDr. Dietrich A. Stephan Ph.D. (Age 54)Founder, President & Director Comp: $836.58kKey CompetitorsPhio PharmaceuticalsNASDAQ:PHIOHistogenNASDAQ:HSTOAllarity TherapeuticsNASDAQ:ALLRClearmind MedicineNASDAQ:CMNDSalarius PharmaceuticalsNASDAQ:SLRXView All CompetitorsInsidersCorp SymetryxSold 129,108 sharesTotal: $185,915.52 ($1.44/share)Corp SymetryxSold 3,376 sharesTotal: $4,861.44 ($1.44/share)Corp SymetryxSold 74,852 sharesTotal: $134,733.60 ($1.80/share)Corp SymetryxBought 61,076 shares on 9/1/2023Total: $59,854.48 ($0.98/share)View All Insider Transactions NBSE Stock Analysis - Frequently Asked Questions How have NBSE shares performed in 2024? NeuBase Therapeutics' stock was trading at $0.7401 at the beginning of the year. Since then, NBSE stock has decreased by 42.6% and is now trading at $0.4251. View the best growth stocks for 2024 here. Are investors shorting NeuBase Therapeutics? NeuBase Therapeutics saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 80,500 shares, a decrease of 59.7% from the February 29th total of 199,800 shares. Based on an average trading volume of 227,500 shares, the short-interest ratio is presently 0.4 days. Approximately 2.7% of the shares of the company are sold short. View NeuBase Therapeutics' Short Interest. When is NeuBase Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our NBSE earnings forecast. How were NeuBase Therapeutics' earnings last quarter? NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its earnings results on Thursday, December, 23rd. The company reported ($4.20) earnings per share for the quarter, beating analysts' consensus estimates of ($4.60) by $0.40. When did NeuBase Therapeutics' stock split? NeuBase Therapeutics shares reverse split before market open on Thursday, June 15th 2023. The 1-20 reverse split was announced on Thursday, June 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of NeuBase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV). Who are NeuBase Therapeutics' major shareholders? NeuBase Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Corp Symetryx, Dietrich A Stephan, Eric I Richman, Todd P Branning and William Roland Mann. View institutional ownership trends. How do I buy shares of NeuBase Therapeutics? Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBSE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuBase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.